Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Inclusion Criteria: * Histologically confirmed PTCL NOS, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, hepatosplenic T-cell lymphoma, ALCL (ALK-1 negative), or patients with ALK 1 expressing ALCL (ALK-1 positive) who have relapsed disease after ASCT * Age ≥21 years * Written informed consent * Progressive disease following at least one systemic therapy or refractory to at least one prior systemic therapy * Measurable disease according to the IWC criteria and/or measurable bone marrow disease by flow cytometry or morphology * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Absolute neutrophil count of ≥1000 × 10(9)cells/L * Serum potassium ≥3.8 mmol/L and magnesium ≥0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria) * Negative urine or serum pregnancy test on females of childbearing potential * All females of childbearing potential and males must use an effective barrier method of contraception during the treatment period and for at least 1 month thereafter. Exclusion Criteria: * Chemotherapy or immunotherapy within 3 weeks of study entry * Concomitant use of any other anti-cancer therapy * Concomitant use of any other investigational agent * Any known cardiac abnormalities such as: * Congenital long QT syndrome; * QTcF interval \>480 milliseconds (msec); * A myocardial infarction within 12 months of study entry; * Other significant ECG abnormalities including 2nd atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate \< 50 beats/ min). * An ECG recorded at screening showing significant ST depression (ST depression of ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec at the end of the QRS complex). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present; * Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction \<40% by MUGA scan or \<50% by echocardiogram and/or MRI; * A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD); * Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above); * Any cardiac arrhythmia requiring anti-arrhythmic medication; * Serum potassium \<3.8 mmol/L or serum magnesium \<0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria) * Concomitant use of drugs that may cause a prolongation of the QTcF * Concomitant use of CYP3A4 inhibitors * Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule * Concomitant use of warfarin due to a potential drug interaction * Clinically significant active infection * Known infection with human immunodeficiency virus (HIV) * Patient has known clinically active hepatitis B or C * Previous extensive radiotherapy involving ≥30% of bone marrow (e.g., whole pelvis, half spine), excluding patients who have had total body irradiation as part of a conditioning regimen for stem cell transplant * Major surgery within 2 weeks of study entry * Peripheral neuropathy or neuropathic pain of Grade 2 or worse * Platelet count \<50 × 109 cells/L or platelet count \<30 × 109 cells/L if bone marrow disease involvement is documented * Serum creatinine \>2.0 × ULN * Patients who are pregnant or breast-feeding * Patient has known hypersensitivity to any components of bortezomib (such as boron, mannitol), or panobinostat